We are currently not shipping Nulojix
Information about Nulojix (Belatacept)
Nulojix (generic name: belatacept) is an immunosuppressive medication used to prevent organ rejection following kidney transplantation. It is a fusion protein that specifically targets the co-stimulatory signals required for T-cell activation, which are involved in the immune response against the transplanted organ. By inhibiting this signaling pathway, Nulojix suppresses the immune system to reduce the risk of transplant rejection.
Belatacept is typically used in combination with other immunosuppressive agents to help prevent rejection in kidney transplant recipients, and it may be particularly beneficial for patients who are at higher risk for kidney transplant rejection or who need long-term immunosuppressive therapy.
Product Highlights
- Nulojix is indicated for the prophylaxis (prevention) of acute organ rejection in adults who have received a kidney transplant. It is used as part of a regimen that includes other immunosuppressive agents (e.g., corticosteroids and mycophenolate mofetil).
- Nulojix is specifically recommended for kidney transplant patients who are Epstein-Barr virus (EBV) seropositive. This is due to the higher risk of post-transplant lymphoproliferative disorder (PTLD) in EBV-negative recipients when receiving belatacept.
Key Ingredient
Key Benefits
- Nulojix significantly reduces the incidence of acute kidney transplant rejection, particularly when used in combination with other immunosuppressive agents.
- Compared to traditional immunosuppressive drugs, belatacept has been associated with a lower risk of certain side effects, such as nephrotoxicity (kidney toxicity) and high blood pressure, which are common with other immunosuppressants.
- Studies suggest that Nulojix may help maintain long-term kidney function by more specifically targeting immune responses without overly suppressing the immune system.
- Nulojix is used as part of a steroid-sparing regimen, meaning that patients may need lower doses of corticosteroids, which can have severe long-term side effects (e.g., diabetes, osteoporosis, and weight gain).
Direction of Use
- Nulojix is given as an intravenous (IV) infusion by a healthcare provider. The infusion is typically given over a period of 30 minutes, depending on the patient's needs and response.
- The usual dosing schedule involves a series of initial infusions over the first few weeks after a kidney transplant (usually on Days 1, 5, 14, and 28). After that, the medication is administered once every four weeks. The exact schedule may vary based on the patient's condition and response to treatment.
- Nulojix is usually administered as part of a combination therapy with other immunosuppressive agents, such as mycophenolate mofetil or tacrolimus, to further reduce the risk of rejection.
Safety Concerns
- As Nulojix suppresses the immune system, it increases the risk of infections, including bacterial, viral, fungal, and opportunistic infections. Patients should be closely observed for any signs of infection.
- Belatacept has been associated with an increased risk of PTLD, particularly in patients who are Epstein-Barr virus (EBV) negative at the time of transplantation. Patients who are EBV-negative should avoid Nulojix.
- There is an increased risk of malignancies, including skin cancers and other types of tumors, due to the immunosuppressive nature of Nulojix.
- Use of Nulojix may be associated with an increased risk of cardiovascular events, including hypertension and heart disease. Blood pressure and lipid levels should be regularly monitored.
- While Nulojix is designed to prevent kidney transplant rejection, careful monitoring of kidney function is still required to ensure the medication does not inadvertently cause harm.
Avoid Nulojix (Belatacept) If:
- Nulojix should not be used in kidney transplant patients who are Epstein-Barr virus (EBV) negative because of the increased risk of post-transplant lymphoproliferative disorder (PTLD).
- Belatacept should not be used in patients with active or untreated infections due to its immunosuppressive effects, which could exacerbate the infection.
- Do not use Nulojix in patients with a known hypersensitivity to belatacept or any of its components.
- Patients with severe hepatic (liver) or renal (kidney) dysfunction should avoid Nulojix, as it may exacerbate these conditions or lead to adverse effects.
- The safety of Nulojix during pregnancy and breastfeeding has not been fully established. It should only be used during pregnancy if the potential benefits exceed the potential risks to the fetus. It is unclear whether belatacept is excreted in human breast milk, so caution should be taken when administering it to breastfeeding women.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.